|Contents||Vial: GHRP-2 (Growth Hormone Releasing peptide-2) 5mg.
Ampoule: Sterile water for injection 2ml.
|Administration||Intramuscular or subcutaneous injection.|
|Storage||Store at room temperature away from heat and direct sunlight prior to reconstitution. Refrigerate between 2-8’C post reconstitution.|
|Dosage||Adult: SC Growth hormone deficiency Initial: 6 mcg/kg/day. May increase dose gradually. Max: 12.5 mcg/kg/day. HIV-associated wasting or cachexia 5 mcg/kg/day at bedtime. May take on alternate days for patients at increased risk of adverse effects. Max: 5 mg/day.|
|Contraindications||Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.|
|Special Precautions||Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis.|
|Adverse Drug Reactions||Hypothyroidism, peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics.|
|Drug Interactions||High doses of corticosteroid may inhibit growth-promoting effects of GHRP-2.|